MAPK3 and prostate carcinoma: We demonstrated that, in parallel with the effects on ERK1/2 activation, ARF1 overexpression in normal prostate cells significantly augmented, whereas ARF1 knockdown in prostate cancer cells markedly attenuated cell growth both in cultured cells in vitro and in the mouse xenograft model in vivo.